A Phase I/II Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70.
Phase of Trial: Phase I/II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs ARGX 110 (Primary)
- Indications Cancer; Haematological malignancies; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors argenx
- 31 Aug 2017 Planned number of patients changed from 90 to 100.
- 01 Aug 2017 Results (n=26) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 20 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History